Michael S. Perry - 21 Nov 2022 Form 4 Insider Report for AVITA Medical, Inc. (RCEL)

Reporting relationship: Director
Issuer ticker: RCEL
Reported as of: 21 Nov 2022
Net transaction value: -$178,500
SEC form: 4
Accepted by SEC: 22 Nov 2022, 15:46:47 UTC
Prior SEC filing: 06 Sep 2022
Next SEC filing: 11 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Donna Shiroma, by power of attorney

Key filing fact

Michael S. Perry filed Form 4 for AVITA Medical, Inc. (RCEL) on 22 Nov 2022.

Key facts

This page summarizes Michael S. Perry's Form 4 filing for AVITA Medical, Inc. (RCEL).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 Nov 2022, 15:46.

Change

Previous filing in this sequence was filed on 06 Sep 2022.
Current net transaction value: -$178,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCEL transaction

Common Stock

Options Exercise

Transaction value: $898,500
Shares: +150,000
Change %: +65%
Price: $5.99
Shares after: 379,543
Date: 21 Nov 2022
Ownership: Direct
Footnotes: F1, F2

RCEL transaction

Common Stock

Sale

Transaction value: $1,077,000
Shares: -150,000
Change %: -40%
Price: $7.18
Shares after: 229,543
Date: 21 Nov 2022
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCEL transaction Derivative

Stock Options (Right to Buy)

Options Exercise

Transaction value: $0
Shares: -150,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 21 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $5.99
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The exercise price was converted from A$8.20, which reflects the 100:1 consolidation ratio applied in converting ordinary shares of Predecessor (as defined below) to shares of the Issuer's Common Stock, using the exchange rate as published by the Reserve Bank of Australia in effect on the date of grant (November 30, 2018).

Footnote F2

Includes 634,602 of the Issuer's CHESS Depositary Interests ("CDIs"). CDIs are units of beneficial ownership in shares of common stock of the Issuer that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty, Limited, a subsidiary of ASX Limited, the company that operates the ASX. Five CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. The Reporting Person holds 634,602 CDIs, which translate into 126,920 of the shares of Common Stock set forth above.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.05 to $7.45. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of the shares of Common Stock sold at each separate price within the ranges set forth in this footnote to this Form 4.

Footnote F4

These Stock Options were originally exercisable for ordinary shares of of AVITA Medical, Ltd., an Australian public company and predecessor to the Issuer ("Predecessor"). Pursuant to a scheme of arrangement, completed on June 30, 2020, the Stock Options became exercisable for shares of Common Stock of the Issuer in the ratio of one share of Common Stock for every 100 ordinary shares of Predecessor for which the Stock Options would otherwise have been exercisable.